hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang- 2022-05-10索科利夫卡专家说,晕厥不是头晕不是昏迷也不是眩晕,你们被我说晕了没得?
- 2022-04-25女性癫痫,这些问题你有关心吗?
- 2022-04-13预测癫痫患者再入院风险
- 2022-04-122013国际抗癫痫联合会抗癫痫药用指南
- 2022-04-11临床试验显示XenoPort 银屑病药物胃肠道副作用较严重
- 2022-04-11癫痫治疗障碍仍难以克服
- 预测癫痫患者再入院风险
- 2013国际抗癫痫联合会抗癫痫药用指南
- 临床试验显示XenoPort 银屑病药物胃肠道副作用较严重
- 癫痫治疗障碍仍难以克服
- 抗癫痫药物预防新发癫痫:任重而道远
- JAHA:房颤患者炎症生物标志物和心力衰竭住院风险
- 血清钙水平可预测甲氨蝶呤治疗银屑病的效果
- 癫痫猝死:凶手是谁?
- 美国FDA关于坏死因子阻滞剂、硫唑嘌呤和/或硫唑嘌呤的安全性更新
- 治疗白癜风的方法很多
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 焦虑和疾病认知影响银屑病关节炎患者的健康生活量表
- FDA批准Aptiom用于治疗患者癫痫发作
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- 心率多少正常 如何保持正常心率不变
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 揭露手指月牙的东西 拇指经常有小指(8)
- FDA 批准银屑病新药 ixekizumab
- 由于医生的原因,物「沉默」而且很难进入处方
- DCR: 慢性肾病对局部晚期直肠癌患者接受新辅助放化疗的预后影响
- Medpage Today:不同类型的抗癫痫药物更有利
- 治疗白癜风的方法 牢记这些治疗白癜风更省钱
- 煮螃蟹的方法 这样吃螃蟹味道也不错
- UCB的Vimpat癫痫新适应症在美国获批
- 白癜风防治指南:记住这六点,对你的病情有帮助!
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 生发偏方 4种生发偏方使头发更浓密
- 诺华Cosentyx欧盟批准治疗中重度斑块状银屑病
- 症状性脑瘤治疗费用要多少钱
- 2015年第31届国际高血压大会(IEC)
- 癫痫病的常规治疗工具有哪些
- 治癫痫病哪里好效用好吗
- 早期癫痫病的病因都有什么
- Diabetologia:表现为非蛋白尿的肾功能不全的2型乳癌患者的肾脏结局和全因死亡率
- 第三届内科癫痫及相关疾病新进展论坛
- 欧盟拓展批准优时比抗癫痫药物 Vimpat 用于儿童患者
- 癫痫的病症及治疗方法 四种治疗方法远离癫痫
- 于今癫痫病能于今的好么
- 最有效治疗癫痫病的药物是哪些
- 癫痫发作对卒中患者进行静脉溶栓的仍然转归起效应